DAA, IMO, would not hurt and I would see no reason not to include it in a post cycle therapy (pct) protocol. The principle application would be a "support" compound once we have returned function to the HPTA. By itself, it would not be sufficient to facilitate a restart.
HMG looks to hold some promise but the human studies I've seen reallyl show HMG to be a complement to HCG in increasing and maintaining spermatogenesis. I am not sure how effect HMG alone would be at providing a necessary level of stimulation for the HPTA. So, again, based on what I know there very well could be an opportunity for HMG in post cycle therapy (pct).
That said, I wouldn't run out and scrap what has been substantiated to be effective for the past 20+ years. Unfortunately, that is what often happens with the "next new thing" when it comes to post cycle therapy (pct) - see Trip, Torm, ect. ect.
HMG looks to hold some promise but the human studies I've seen reallyl show HMG to be a complement to HCG in increasing and maintaining spermatogenesis. I am not sure how effect HMG alone would be at providing a necessary level of stimulation for the HPTA. So, again, based on what I know there very well could be an opportunity for HMG in post cycle therapy (pct).
That said, I wouldn't run out and scrap what has been substantiated to be effective for the past 20+ years. Unfortunately, that is what often happens with the "next new thing" when it comes to post cycle therapy (pct) - see Trip, Torm, ect. ect.
Cashout, wanted to get your views on a few other chemicals for post cycle therapy (pct).
D-Aspartic Acid has been shown to positively modulate LH in a lot of studies. I have no idea what the affinity differences and LH boosting properties of DAA and HCG are. DAA is a newer product though, so do you think it could have any place post cycle therapy (pct)?
And what about HMG rather than HCG since it modulates LH and FSH? I don't know what the dose conversion is and if cost would be a factor, but HMG seems like a superior alternative from my vantage point.